# OnCo record paper-meyers-pcodr-clinical-benefit-jama-intern-med-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-meyers-pcodr-clinical-benefit-jama-intern-med-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-meyers-pcodr-clinical-benefit-jama-intern-med-2021" ;
  schema:name "Clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada"@en ;
  schema:description "Of 104 solid-tumour cancer drug decisions by Canada's pan-Canadian Oncology Drug Review from 2011 to 2020, three in four were positive, almost all with conditions, and only half of the recommended drugs had shown that they extend life, by a median of 3.7 months."@en ;
  schema:url <https://onco.cc/key-papers/paper-meyers-pcodr-clinical-benefit-jama-intern-med-2021/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamainternmed.2020.8588>, <https://pubmed.ncbi.nlm.nih.gov/33616606/> ;
  schema:sameAs <https://doi.org/10.1001/jamainternmed.2020.8588> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Meyers DE, Jenei K, Chisamore TM, Gyawali B" ;
  onco:institutions <https://onco.cc/institutions/cda-amc/> ;
  onco:journals <https://onco.cc/journals/jama-internal-medicine/> .